ArticleFrontiers in veterinary science2026
Suspected cumulative neuro-ophthalmic toxicity after chronic oral exposure to the veterinary anesthetic tiletamine: a case report.
Article in Frontiers in veterinary science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tiletamine, commonly formulated with zolazepam as Zoletil Case presentation: A 24-year-old man developed progressive bilateral visual decline (left worse than right) after >1 year of non-medical oral exposure to a suspected tiletamine-containing product obtained online. He also reported persistent dyschromatopsia, dysarthria, and gait instability after cessation. Best-corrected visual acuity was 20/25 (right) and 20/50 (left). Fundus and ultra-widefield imaging were unremarkable. Optical coherence tomography showed bilateral fovea-centered outer retinal/photoreceptor-layer disruption with scattered hyperreflective foci. Full-field electroretinography was within normal limits, whereas visual evoked potentials revealed reduced P100 amplitude in the left eye with preserved latency. Brain MRI demonstrated mild diffuse cerebral and cerebellar sulcal widening compatible with early atrophy. Alternative causes, including inherited retinal degeneration and other established retinotoxic exposures, were not supported by the available evaluation. Short-term follow-up showed clinical stability with limited recovery. Conclusion: This case suggests a possible temporal association between prolonged oral exposure to a suspected tiletamine-containing product and combined retinal and neurological abnormalities. Because toxicological confirmation and independent formulation verification were unavailable, causality cannot be established. The findings highlight the need for One Health-oriented toxicovigilance and longitudinal neuro-ophthalmic monitoring when similar exposure is suspected.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.